Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
5-day change
1st Jan Change
2.77
USD
+0.36%
+6.95%
-12.89%
Lumos Pharma, Inc.'s Equity Buyback announced on August 16, 2022, has expired with 517,468 shares, representing 6.30% for $1.96 million.
The company expired its plan on August 17, 2023.
Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 07
CI
Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024
Mar. 07
Earnings Flash (LUMO) LUMOS PHARMA Reports Q4 Revenue $2.1M
Mar. 07
MT
Lumos Pharma, Inc. Promotes Pisit Pitukcheewanont to Chief Medical Officer
Jan. 04
CI
Oppenheimer Trims Lumos Pharma Price Target to $16 From $17, Maintains Outperform Rating
Dec. 11
MT
Transcript : Lumos Pharma, Inc. - Special Call
Dec. 06
North American Morning Briefing : Stock Futures -2-
Nov. 13
DJ
Transcript : Lumos Pharma, Inc. - Special Call
Nov. 08
Top Premarket Gainers
Nov. 08
MT
Lumos Pharma Phase 2 Trials Targeting Pediatric Growth Hormone Deficiency Meet Endpoints; Shares Surge Premarket
Nov. 08
MT
Lumos Pharma Shares Than Double After Hormone Deficiency Trial Meets All Endpoints
Nov. 07
DJ
Tranche Update on Lumos Pharma, Inc.'s Equity Buyback Plan announced on August 16, 2022.
Nov. 07
CI
Lumos Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 07
CI
Earnings Flash (LUMO) LUMOS PHARMA Posts Q3 Revenue $7,000
Nov. 07
MT
Lumos Pharma, Inc. Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 inPGHD Met All Primary and Secondary Endpoints
Nov. 07
CI
Lumos Pharma Says New Data Shows LUM-201 Restored Growth Hormone Secretion to Similar Levels in Normally Growing Children
23-09-26
MT
Lumos Pharma Announces New Data and Analysis of 15 Subjects from Oragrowth212 Trial Presented At the 2023 ESPE Annual Meeting
23-09-26
CI
Lumos Pharma, Inc. Announces Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
23-09-14
CI
Transcript : Lumos Pharma, Inc. - Special Call
23-09-05
Lumos Pharma, Inc.'s Equity Buyback announced on August 16, 2022, has expired with 517,468 shares, representing 6.30% for $1.96 million.
23-08-16
CI
Cantor Fitzgerald Adjusts Lumos Pharma's Price Target to $10 From $14, Keeps Overweight Rating
23-08-15
MT
Tranche Update on Lumos Pharma, Inc.'s Equity Buyback Plan announced on August 16, 2022.
23-08-10
CI
Oppenheimer Adjusts Lumos Pharma Price Target to $17 From $18, Maintains Outperform Rating
23-08-10
MT
Lumos Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-09
CI
Transcript : Lumos Pharma, Inc., Q2 2023 Earnings Call, Aug 09, 2023
23-08-09
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
More about the company
Last Close Price
2.77
USD
Average target price
23.33
USD
Spread / Average Target
+742.36%
Consensus
1st Jan change
Capi.
-12.89% 22.48M +1.51% 42.75B +49.22% 41.61B +8.57% 41.34B -12.36% 26.59B +8.92% 25.49B -25.13% 18.12B +29.17% 12.24B -3.12% 11.76B +6.35% 11B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1